SCHEMBL1712908

SCHEMBL1712908

N[C@@H](Cc1ccc(N=Nc2ccccc2)cc1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.70
PTGS1 P23219 3/20 0.70
ALPI P09923 1/20 0.70
PKM P14618 1/20 0.70
XIAP P98170 1/20 0.70
TPH1 P17752 2/20 0.55
NOS3 P29474 3/20 0.55
NOS1 P29475 3/20 0.55
NOS2 P35228 3/20 0.55
ALOX15 P16050 3/20 0.51
HIF1A Q16665 3/20 0.51
KDM4E B2RXH2 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
SLC1A3 P43003 1/20 0.51
SLC1A2 P43004 1/20 0.51
SLC1A1 P43005 1/20 0.51
USP2 O75604 1/20 0.51
EGFR P00533 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19368127 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL5286259 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL12272708 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4338268 1.00 SLC7A5 (0.70) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL4285203 0.95 SLC7A5 (0.64) SLC7A5PTGS1ALPIPKMXIAP
Azobenzene SCHEMBL23038628 0.95 SLC7A5 (0.79) SLC7A5PTGS1ALPIPKMXIAP
Azobenzene SCHEMBL8497483 0.92 SLC7A5 (0.75) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28349276 0.87 TPH1 (0.60) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28349278 0.87 TPH1 (0.60) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28366916 0.86 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243472-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-07-31 US claimed
US-20230212535-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-07-06 US claimed
EP-4198125-A2 PIF1-LIKE HELICASE AND USE THEREOF Qitan Technology Ltd., Beijing (CN) 2023-06-21 EP claimed
US-11525125-B2 Modified helicases OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2022-12-13 US claimed
EP-4063382-A9 PIF1-LIKE HELICASE AND APPLICATION THEREOF Qitan Technology Ltd., Beijing (CN) 2022-11-16 EP claimed
EP-4063382-A1 PIF1-LIKE HELICASE AND APPLICATION THEREOF Qitan Technology Ltd., Beijing (CN) 2022-09-28 EP claimed
US-20220290223-A1 PIF1-LIKE HELICASE AND USE THEREOF Qitan Technology Ltd. (CN) 2022-09-15 US claimed
US-20210009971-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2021-01-14 US claimed
EP-3575410-A2 MODIFIED ENZYMES Oxford Nanopore Technologies Limited (GB) 2019-12-04 EP claimed
US-20180037874-A9 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2018-02-08 US claimed
WO-2015055981-A2 MODIFIED ENZYMES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2015-04-23 WO claimed
US-8658394-B2 Methods, cells and systems for incorporating non-canonical amino acids into proteins WATERSTONE PHARMACEUTICALS (CN) 2014-02-25 US claimed
WO-2014013260-A1 MODIFIED HELICASES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2014-01-23 WO claimed
EP-2344529-B1 NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF IPSEN PHARMA SAS (FR) 2013-06-05 EP claimed
US-20120237971-A1 METHODS, CELLS AND SYSTEMS FOR INCORPORATING NON-CANONICAL AMINO ACIDS INTO PROTEINS WATERSTONE PHARMACEUTICALS (CN) 2012-09-20 US claimed
CN-102171246-A Novel octapeptide compounds derived from somatostatin and therapeutic uses thereof IPSEN PHARMA SAS 2011-08-31 CN claimed
US-20110178013-A1 NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF IPSEN PHARMA S.A.S. (FR) 2011-07-21 US claimed
EP-2344529-A1 NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF IPSEN PHARMA S.A.S. (FR) 2011-07-20 EP claimed
WO-2010037930-A1 NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THERAPEUTIC USE THEREOF IPSEN PHARMA S.A.S. (FR) 2010-04-08 WO claimed
EP-1483282-B1 RIBOZYMES WITH BROAD tRNA AMINOACYLATION ACTIVITY UNIV NEW YORK STATE RES FOUND (US) 2009-07-29 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178013-A1 NOVEL OCTAPEPTIDE COMPOUNDS DERIVED FROM SOMATOSTATIN AND THE THERAPEUTIC USE THEREOF SSTR5, SSTR1, SSTR3 SLC7A5 162/4885PTGS1 1234/4885ALPI 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.